Rather than ranking vendors, the more useful question for a sponsor or CRO to actually answer is what separates a platform genuinely built for pharmacovigilance from one that simply stores and routes cases. That distinction determines whether a platform reduces real risk or just organizes it into a searchable queue.
Real-time, field-level validation. A platform should validate case data against ICH E2B(R3) and regional gateway rules as it's entered, not just before final submission catching errors when they're cheapest to fix.
MedDRA coding grounded in the actual database hierarchy. Coding should be pulled from the current MedDRA structure and cross-checked against historical precedent, not generated from pattern-matching or left to individual reviewer judgment alone.
Case quality scoring before submission. Every case should carry a completeness and quality signal before it reaches the gateway, not just a pass/fail check discovered through a later query.
An audit trail that captures reasoning, not just actions. Regulatory reviewers want to understand why a decision was made, not just that a timestamp exists. Strong platforms log confidence levels and alternative considerations alongside the final output.
Root-cause visibility across cases, not just case-by-case fixes. When a query or rejection occurs, a strong platform makes it easy to see whether the same underlying cause is recurring elsewhere in the caseload.
Literature surveillance connected to case creation. Safety-relevant literature findings should feed directly into case workflow, rather than existing as a separate manual research process disconnected from case management.
| Capability | Weak Platform | Strong Platform |
|---|---|---|
| Validation | Before final submission only | Real-time, field-level |
| Coding | Free-text or manual lookup | Database hierarchy plus historical precedent |
| Case quality | Uniform treatment | Scored before submission |
| Audit trail | Logs actions | Captures reasoning and confidence |
| Root cause | Fixed case by case | Patterns visible across cases |
| Literature | Separate manual process | Connected to case creation |
Regulatory expectations for pharmacovigilance extend to consistency and defensibility across an entire safety program, not just individual case handling. A platform that only stores and routes cases leaves that consistency dependent on manual reviewer discipline rather than the system itself.
AI VigiCheck applies real-time validation across more than 200 rules spanning ICH E2B(R3), EMA EVWEB, and FDA ESG, with a completeness and quality score assigned before every submission. The Medical Coding Assistant pulls terms directly from the MedDRA database and falls back to historical decisions for similar cases, saving a final code only on human confirmation. Evidence IQ connects literature surveillance directly to case creation rather than treating it as a separate workflow.
See how Cloudbyz's PV platform approaches case validation, coding, and quality book a demo